NCT02284230

The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure

Glycaemic and Cardiovascular Efficacy of Liraglutide in Prediabetic Patients With End-stage Renal Disease

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Bo Feldt-Rasmussen · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The present study will examine the effects of liraglutide treatment during 26 weeks on several cardiovascular risk factors in patients with prediabetes and end-stage renal disease (ESRD). The primary objective is to determine the efficacy of the treatment on glucose tolerance evaluated during a 3h 75g-oral glucose tolerance test (OGTT). Secondary objectives include various clinical and biochemical cardiovascular and safety parameters. We hypothesise that treatment with liraglutide can improve glucose tolerance in prediabetic patients with ESRD by normalizing plasma glucose excursions during an OGTT and ameliorate other cardiovascular risk factors.

Conditions

• Kidney Failure, Chronic
• Prediabetic State

Interventions

Type	Name	Description
DRUG	Liraglutide
DRUG	Placebo

Timeline

• Start date: 2014-12-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2014-11-05
• Last updated: 2015-08-24

Locations

1 site across 1 country: Denmark